AlphaMab is attracting attention as the Suzhou-based biotech has filed China's first PD-L1 antibody, giving it a lead over larger and multinational competitors. The venture’s winning strategy lies in staying ahead of the curve, CEO Xu Ting told PharmAsia News in an exclusive interview.
BEIJING – Compared to the US, China has relatively few innovative therapies, which leaves much room for smaller companies to improve on current treatments and thrive in the process.
In 2015, the US FDA set a record for innovative new drug approvals, while China still lags far behind
Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.
Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.
InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.
Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.
